登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，4月2日，Why inequality could spread COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-03

  • Why inequality could spread COVID-19

    Faheem Ahmed

    Na'eem Ahmed

    Christopher Pissarides

    Joseph Stiglitz

    Open AccessPublished:April 02, 2020DOI:https://doi.org/10.1016/S2468-2667(20)30085-2

    Pandemics rarely affect all people in a uniform way. The Black Death in the 14th century reduced the global population by a third, with the highest number of deaths observed among the poorest populations.1 Densely populated with malnourished and overworked peasants, medieval Europe was a fertile breeding ground for the bubonic plague. Seven centuries on—with a global gross domestic product of almost US$100 trillion—is our world adequately resourced to prevent another pandemic?2 Current evidence from the coronavirus disease 2019 (COVID-19) pandemic would suggest otherwise.

  • 原文来源：https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30085-2/fulltext
82浏览量
原文链接
相关报告

  • 《LANCET，4月2日，Caution and clarity required in the use of chloroquine for COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-03
    • Caution and clarity required in the use of chloroquine for COVID-19 Yin Kwan Wong Jing Yang Yingke He Published:April 02, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30093-X As the coronavirus disease 2019 (COVID-19) outbreak continues to spread rapidly, efforts are ongoing in China and around the world to develop effective treatments. Among the drugs being tested for COVID-19 in China is chloroquine, which was reported on Feb 4, 2020, to inhibit severe acute respiratory syndrome coronavirus 2 in vitro. The drug was rapidly pushed to clinical testing as an experimental treatment in China; on Feb 15, 2020, it was included in the sixth version of the COVID-19 treatment guidelines by the National Health Commission of the People's Republic of China. This guideline established the use of chloroquine nationwide for patients with COVID-19, at a recommended adult dose of 500 mg twice per day for no more than 10 days.
    24浏览量
    原文链接

  • 《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment? – Authors' reply》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-04
    • Baricitinib for COVID-19: a suitable treatment? – Authors' reply Peter J Richardson，Mario Corbellino，Justin Stebbing Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30270-X We thank Ennio Favalli and colleagues for their Correspondence regarding our suggestion to use baricitinib for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.1, 2 We also appreciate their recognition that inhibition of numb-associated kinase enzymes could indeed be beneficial in preventing virus infectivity via inhibition of clathrin-mediated endocytosis. We welcome the opportunity to more fully explain the possible use of baricitinib in the current pandemic. Indeed, we accept that using a JAK1 and JAK2 inhibitor to treat a viral disease might appear illogical given that the antiviral effects of interferons are largely mediated by the JAK–STAT signalling pathway. However, the administration of pegylated-interferon has not had the beneficial antiviral effects originally hoped for,4 and clinical trials with interferons have yielded inconsistent results, with pathogenic effects of interferons being observed in some viral infections.
    93浏览量
    原文链接